---
ID: P78
Title: Allergy & Anaphylaxis Prevention System
Registry: CLAI-OS Human Good Systems (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P78: Allergy & Anaphylaxis Prevention System

## Abstract

Anaphylaxis remains underrecognized and undertreated globally despite rapid reversibility with early epinephrine. Delays occur from misclassified severity, antihistamine over-reliance, and fear of epinephrine adverse effects. P78 removes ambiguity through compiler-level emergency logic prioritizing physiologic instability over diagnostic hesitation, while addressing structural misinformation surrounding food allergy, vaccine allergy, radiocontrast reactions, and medication allergy overlabeling.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

### Clinical Logic

- WHO/WAO diagnostic recognition with immediate intramuscular epinephrine enforcement (0.01 mg/kg anterolateral thigh; repeat every 5 to 15 minutes) and explicit rejection of antihistamine-first protocols.
- Sixty-second emergency protocol with positioning enforcement (supine, leg elevation, left lateral tilt in pregnancy), airway preparation, and glucagon for beta-blocker refractory hypotension.
- Cross-reactivity correction (shellfish is not iodine allergy; penicillin-cephalosporin side-chain stratification; latex-fruit syndrome; vaccine excipient differentiation).
- Perioperative allergy surveillance for chlorhexidine, latex, neuromuscular blocking agents, antibiotics, and contrast media with standardized reaction documentation.
- Allergy de-labeling pathways with low-risk penicillin testing, oral challenge eligibility, and historical reaction stratification to reduce inappropriate broad-spectrum antibiotic use.

### Safety Posture

- Hesitation Elimination Architecture enforces epinephrine as first-line therapy whenever anaphylaxis criteria are met, with no absolute contraindications and automatic override of antihistamine-first orders.
- Biphasic Risk Stratification governs post-event observation with epinephrine auto-injector prescription, trigger education, written emergency action plans, and allergy referral automation.
- Allergy Verification Engine performs longitudinal de-labeling to reduce lifelong inappropriate medication avoidance that drives antimicrobial resistance and inferior therapy selection.

### Integration Points

- **Upstream:** P71 (Pediatric Guardian) for pediatric dosing; P72 (Maternal Protector) for pregnancy-safe intervention.
- **Downstream:** P75 (Stewardship) for de-labeling antimicrobial synergy; P76 (Vaccine Validator) for immunization reaction management.

Like all Tier II modules, this module shares the common CLAI-OS methodological substrate: deterministic safety compilation, context-sensitive adaptation, closed-loop accountability, federated learning via encrypted gradients rather than raw data, and graceful degradation under bandwidth, power, staffing, and infrastructure failure.

## Merits

- Removes the documented hesitation failure mode — misclassified severity, antihistamine over-reliance, epinephrine fear — by making first-line treatment a compiler-level enforcement.
- Proposed validation metrics: time-to-epinephrine administration, anaphylaxis mortality rate, allergy label accuracy, penicillin de-labeling success rate, perioperative hypersensitivity detection, and biphasic reaction capture rate.
- Attacks allergy overlabeling as a population-level stewardship problem with downstream antimicrobial resistance consequences.

The merits above are design-level statements drawn from the published abstract and methodology. No peer-reviewed outcome evaluations accompany this release; the listed indicators are the metrics the design proposes for validation. Status: partial documentation — expansion pending.

## Guidance for Use

### Intended Setting

Emergency departments, perioperative and anesthesia services, allergy clinics, vaccination sites, and infusion centers in low-resource-first deployment, where anaphylaxis recognition and epinephrine access are least reliable. The module is intended for clinical human-good applications; consistent with the Tier II architecture, it is specified for degraded-infrastructure operation, with offline synchronization, battery operation, SMS fallback, and low-bandwidth mode where power or connectivity is unstable.

### Prerequisites

- Epinephrine availability (including pediatric dosing capability) confirmed at every covered site; local referral pathway for allergy testing and oral challenge established.
- Supervision by licensed clinicians who retain final authority for every patient decision; the module is a governance layer, not an autonomous practitioner.
- Local validation of all thresholds and pathways against jurisdictional guidelines, formulary, and scope-of-practice rules before any clinical use.
- An accountability chain (verification, documentation, ownership, follow-up, escalation) as required by the shared CLAI-OS closed-loop methodology.
- For integrated deployments: HL7 FHIR R4-compatible infrastructure; the architecture is specified to degrade gracefully (offline synchronization, battery operation, SMS fallback, low-bandwidth mode) where infrastructure is unstable.

### Misuse

- Do not use de-labeling logic to override documented severe reactions without specialist assessment; risk stratification and challenge eligibility are gated, not automatic.
- Do not present module output as a clinical diagnosis, prescription, or substitute for professional judgment.
- Do not use to deny, delay, or ration care on the basis of race, disability, wealth, insurance status, or any protected characteristic; the design explicitly prohibits such inputs.
- Do not attempt to reconstruct or reimplement the withheld prompt body from this document; the abstract and methodology are published for examination and validation, not for unsupervised clinical deployment.
- Do not deploy as an autonomous system that overrides documented patient wishes, assigns futility, initiates withdrawal of care, or delays emergent intervention; the architecture carries hard-stops against each of these.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
